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DOI 10.1016/j.ccr.2012.02.008SUMMARYWe and others previously identified NKX2-1, also known as TITF1 and TTF-1, as a lineage-survival oncogene
in lung adenocarcinomas. Here we show that NKX2-1 induces the expression of the receptor tyrosine kinase-
like orphan receptor 1 (ROR1), which in turn sustains a favorable balance between prosurvival PI3K-AKT and
pro-apoptotic p38 signaling, in part through ROR1 kinase-dependent c-Src activation, as well as kinase
activity-independent sustainment of the EGFR-ERBB3 association, ERBB3 phosphorylation, and conse-
quential PI3K activation. Notably, ROR1 knockdown effectively inhibited lung adenocarcinoma cell lines,
irrespective of their EGFR status, including those with resistance to the EGFR tyrosine kinase inhibitor
gefitinib. Our findings thus identify ROR1 as an ‘‘Achilles’ heel’’ in lung adenocarcinoma, warranting future
development of therapeutic strategies for this devastating cancer.INTRODUCTION
It is well understood that oncogene addiction is present in certain
cancers, with lung adenocarcinomas carrying epidermal growth
factor receptor (EGFR) mutations among the best examples
(Weinstein, 2002). Emerging evidence, though currently sparse,
suggests that ‘‘lineage-specific transcription factors’’ with devel-
opmental roles in normal progenitor cells of particular lineages
may also confer dependency for survival to certain types of
cancer cells (Garraway and Sellers, 2006). The basic helix-
loop-helix (bHLH) transcription factor MITF in melanoma has
been proposed as an archetypal prototype. Along this line, our
previous studies demonstrated that achaete-scute homolog 1
(ASH1)/achaete-scute complex-like 1, a bHLH protein indis-Significance
NKX2-1-induced ROR1 is required to sustain a favorable bal
apoptotic p38 pathway; the collapse of which elicits ‘‘oncogen
kinase with a ‘‘sustainer role’’ for the EGFR-ERBB3-mediated s
MET amplification, and HGF overexpression, may arise in lung
ment and lead to tumor resistance of the treatment. Such div
be targeted to prevent expansion of resistant clones. From
ROR1 inhibition appears to be effective in treatment of gefitin
mechanisms.
348 Cancer Cell 21, 348–361, March 20, 2012 ª2012 Elsevier Inc.pensable for pulmonary neuroendocrine cell development, is
also required for survival of lung cancers with neuroendocrine
features, such as small cell lung cancers (Nishikawa et al.,
2011; Osada et al., 2005, 2008).
Lung cancer is the leading cause of cancer death, whereas
adenocarcinomas arising from peripheral lung are the most
frequent histological type and exhibit the highest degree of
heterogeneity. NKX2-1, a homeodomain transcription factor
also known as TITF1 and TTF-1, plays an essential role in periph-
eral lung development, and NKX2-1 deficiency in mice results in
lung aplasia (Kimura et al., 1996). We previously reported
that NKX2-1 is a reliable lineage marker for terminal respiratory
unit (TRU) cells, as well as for ‘‘TRU-type’’ adenocarcinomas
with distinct gene expression profiles, which show abundantance between prosurvival PI3K-AKT signaling and the pro-
ic shock.’’ ROR1 was also identified as a receptor tyrosine
ignaling. Mechanisms, such as a secondary EGFRmutation,
adenocarcinomas of patients undergoing EGFR-TKI treat-
erse mechanisms make it difficult to predict which should
a clinical point of view, it is thus of particular interest that
ib-resistant lung adenocarcinomas with various resistance
Figure 1. ROR1 Is Transactivated by NKX2-1
(A) WB analysis of NKX2-1-transfected HPL1D.
(B) WB analysis of siNKX2-1-introduced NKX2-1+/ROR1+ lung adenocarcinoma cell lines. siControl, negative control siRNA; siNKX2-1 #1 and #2, siRNAs against
NKX2-1.
(C) Luciferase reporter assay of ROR1 promoter showing reduced activity in response to NKX2-1 silencing in a stable NKX2-1 transfectant of HPL1D. Data are
shown as the mean ± SD (n = 3).
(D) Hierarchical clustering analysis of non-small-cell lung cancers using a microarray dataset along with information regarding the relationship of ROR1
expression with EGFR and K-ras mutations.
(E) Western blot analysis of ROR1 and NKX2-1 in lung adenocarcinoma and normal lung epithelial cell lines. NL, normal lung; AD, lung adenocarcinoma.
(F) Representative ROR1 staining in lung adenocarcinoma specimens and a summary of immunohistochemical analysis (n = 25). Scale bar, 100 mm. See also
Figure S1 and Table S1.
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ROR1 Sustains EGFR-Initiated Prosurvival SignalingNKX2-1 expression, as well as characteristic clinicopathologic
and genetic features, including a significant association with
EGFR mutations (Takeuchi et al., 2006; Yatabe et al., 2002,
2005). We further identified NKX2-1 as a lineage-survival onco-
gene in lung adenocarcinoma (Tanaka et al., 2007); other inves-
tigators reached similar conclusions through genome-wide
searches for focal genomic aberrations (Kendall et al., 2007;
Kwei et al., 2008; Weir et al., 2007).
Previous findings, including ours, thus clearly indicate the
requirement of sustained NKX2-1 expression for lung adenocar-
cinoma survival, though how NKX2-1 mediates survival signals
remains elusive. It should be noted that NKX2-1 itself is well
known to play indispensable roles in the maintenance of normal
lung physiology, such as transcriptional activation of surfactant
protein genes (Boggaram, 2009). In the present study, we there-
fore aimed to elucidate downstream signaling by NKX2-1, sincesuch understanding appears to be a crucial step in the develop-
ment of a therapeutic strategy for targeting NKX2-1-mediated
survival signaling.
RESULTS
Identification of ROR1 as a Direct Transcriptional Target
for NKX2-1
To better understand how NKX2-1 mediates survival signals
in lung adenocarcinomas, we performed microarray analysis
using HPL1D, an immortalized human peripheral lung epithelial
cell line (Masuda et al., 1997), which was stably introduced
with NKX2-1. Consequently, ROR1 was identified among the
most highly upregulated genes (Figure S1A available online).
NKX2-1-mediated ROR1 induction was validated by western
blot analysis using NKX2-1 transfectants (Figure 1A), as well asCancer Cell 21, 348–361, March 20, 2012 ª2012 Elsevier Inc. 349
Figure 2. ROR1 Sustains Lung Adenocarci-
noma Survival
(A) Assays for measuring the effects of ROR1
knockdown in growth inhibition and apoptosis
induction in lung adenocarcinoma cell lines.
siControl, negative control siRNA; siROR1 #1 to
#3, siRNA against ROR1. Data are shown as the
mean ± SD (n = 3).
(B) In vivo treatment of xenografts with ROR1
siRNA. Two weeks after intratumoral siRNA
injection, photographs were obtained and tumor
weights measured. Data are shown as the mean ±
SD (n = 7).
(C) Alleviation of siNKX2-1-mediated growth inhi-
bition by ROR1 introduction. Colonies were
counted two weeks after cotransfection of the
expression vectors of ROR1 and short hairpin RNA
against NKX2-1 in NKX2-1+/ROR1+ NCI-H358.
Data are shown as the mean ± SD (n = 3). *p < 0.05
versus VC+shNKX2-1, as determined by
Student’s t test.
(D) Colorimetric assays of cells treated with
siROR1, along with wild-type ROR1 [ROR1-
mut(si#1)] or kinase-dead ROR1 [ROR1-KD
mut(si#1)], each with silent mutations at the siRNA
binding site. Data are shown as the mean ± SD
(n = 3). **p < 0.001 versus siROR1#1+ROR1, as
determined by Student’s t test.
(E) In vivo tumor growth assay in stablewild-type or
kinase-dead ROR1 transfectants of MSTO-211H.
Three weeks after subcutaneous inoculation,
tumor weights were measured. Data are shown
as the mean ± SD (n = 5). See also Figure S2.
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ROR1 Sustains EGFR-Initiated Prosurvival Signalinglung adenocarcinoma cell lines treated with siRNA against
NKX2-1 (siNKX2-1; Figure 1B). A luciferase reporter assay with
the 1.0 kb human ROR1 promoter region showed its NKX2-1-
dependent activation (Figure 1C), and a chromatin immunopre-
cipitation (ChIP) assay revealed direct binding of NKX2-1 to
the ROR1 promoter (Figure S1B), demonstrating that ROR1 is
a direct transcriptional target for NKX2-1. Co-expression of
NKX2-1 and ROR1 was preferentially observed in adenocarci-
nomas in analysis of our previousmicroarray dataset of 149 non-
small lung cancer patients (Figure 1D; Takeuchi et al., 2006; GEO
accession number: GSE11969), whereas the presence of EGFR
mutations was found to be associated with a high expression of
ROR1. A similar association between NKX2-1 andROR1 expres-350 Cancer Cell 21, 348–361, March 20, 2012 ª2012 Elsevier Inc.sion was also confirmed at the protein
level in panels of lung adenocarcinoma
cell lines and tumor specimens (Figures
1E and 1F and Table S1). However, we
also noted some instances of NKX2-1-/
ROR1+, suggesting that the expression
of ROR1 may be also regulated by other
transcription factors.
Involvement of ROR1 in NKX2-1-
Mediated Survival Signaling in Lung
Adenocarcinomas
Next,weexaminedwhetherROR1knock-
down affects survival in lung adenocarci-noma cells. siROR1 treatment was shown to induce significant
growth inhibition of ROR1-positive lung adenocarcinoma cell
lines in association with apoptosis induction, whereas ROR1-
negative lung adenocarcinoma cell lines, as well as primary
normal lung epithelial cells, did not show any growth inhibition
(Figures 2A and S2A–S2C). In addition, intratumoral injection of
ROR1 siRNAs with atelocollagen significantly reduced in vivo
growth of NCI-H1975 xenografts (Figure 2B). We also investi-
gated whether exogenously introduced ROR1 could mitigate
NKX2-1-knockdown-induced growth inhibition. Forced ROR1
expression resulted in significant, though not complete, allevia-
tion of growth inhibition imposed by the expression of short
hairpin RNA against NKX2-1 in NKX2-1+/ROR1+ NCI-H358 cells,
Figure 3. ROR1 Affects Both PI3K-AKT Prosurvival and Pro-
Apoptotic p38 Signaling
(A) WB analysis of the prosurvival and pro-apoptotic signaling molecules in
siROR1-treated adenocarcinoma cells.
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ROR1 Sustains EGFR-Initiated Prosurvival Signalingsupporting the notion that NKX2-1-induced survival signaling is
conferred, at least in part, through induction of ROR1 (Figure 2C).
Interestingly, we found that the wild-type but not kinase-dead
ROR1 with silent mutations at the siRNA binding site was able
to counteract siROR1-induced growth inhibition (Figure 2D).
Concordantly, forced expression of wild-type ROR1 but not
kinase-deadROR1 inROR1-negativeMSTO-211Hcells at a level
comparable to that in NCI-H1975 cells enhanced in vivo growth
of the xenografts (Figures 2E, S2D, and S2E), suggesting that
ROR1 kinase activity is required to fully confer a growth
advantage.
Identification of ROR1-EGFR Interaction Sustaining
EGFR-ERBB3-PI3K Signaling
We also examined how ROR1 mediates survival signals in lung
adenocarcinomas. ROR1 knockdown decreased phosphoryla-
tions of ERBB3, c-Src, and AKT in NKX2-1+/ROR1+ NCI-
H1975, SK-LC-5, and NCI-H358 cells (Figures 3A, S3A, and
S3B). siROR1 treatment also reduced phosphorylation of
FOXO1, downstream of AKT, whereas p38 phosphorylation
was induced in siROR1-treated cells, in association with
increased phosphorylations of its upstream kinases ASK1 and
MKK3/6. In contrast, phosphorylations of EGFR and ERK1/2
were not affected by ROR1 knockdown. Introduction of exoge-
nous wild-type ROR1 with silent mutations at the siRNA binding
site cancelled effects on downstream signaling, demonstrating
the specificity of siRNA-mediated ROR1 knockdown (Figure 3B).
We noted that forced expression of kinase-dead ROR1 with the
silent mutations restored ERBB3 phosphorylation, whereas it
failed to mitigate siROR1-induced effects on c-Src, p38, and
AKT phosphorylations (Figure 3B). Conversely, opposite effects
on the phosphorylations of potential downstream molecules
were observed in wild-type, but not kinase-dead, ROR1-intro-
duced MSTO-211H xenografts, whereas increased ERBB3
phosphorylation was detected in both wild-type and kinase-
dead ROR1-introduced xenografts (Figure 3C).
EGFR by itself is an efficient initiator of ERK through homo-
dimer formation, though it is a poor activator of PI3K signaling
(Sharma and Settleman, 2009). In addition, EGF-induced EGFR
activation is linked to PI3K through phosphorylation of intrinsi-
cally kinase-deficient ERBB3 but not EGFR in lung adenocarci-
noma cells (Engelman et al., 2005; Rothenberg et al., 2008).
We found that ROR1 knockdown selectively diminished EGF
treatment-induced ERBB3 phosphorylation without appreciably
affecting the phosphorylation of EGFR itself in NCI-H1975 and
SK-LC-5 cells (Figure 4A), which appeared to be consistent
with the lack of effects seen with ROR1 knockdown on ERK
phosphorylation. ROR1 knockdown also abrogated EGF-
induced phosphorylation of AKT and FOXO1, whereas
decreased c-Src phosphorylation and induction of p38 phos-
phorylation were elicited by siROR1 treatment regardless of
the presence or absence of EGF. Marked nuclear retention,
hence activation of apoptosis-inducing FOXO1, a target of the(B) WB analysis of lung adenocarcinoma cells concurrently treated with
siROR1 and RNAi-resistant wild-type ROR1 [ROR1-mut(si#1)] or kinase-dead
ROR1 [ROR1-KD mut(si#1)].
(C) WB analysis of signaling molecules in ROR1 stable transfectants. ROR1-
KD, kinase-dead ROR1. See also Figure S3.
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Figure 4. ROR1 Sustains EGF-Induced Signaling through ERBB3
(A) WB analysis of downstream molecules in EGF-treated and ROR1-silenced NCI-H1975 and SK-LC-5.
(B) Immunofluorescence staining of FOXO1 in ROR1-silenced NCI-H1975 in the presence or absence of EGF. Scale bar, 30 mm. Strv, serum starved.
(C) IP-WB analysis of EGF-stimulated association of EGFR with ROR1 or ERBB3 in NCI-H1975. Strv, serum starved.
(D) IP-WB analysis of EGFR-ERBB3 association in response to EGF, with and without siROR1 treatment, in NCI-H1975. Strv, serum starved.
(E) IP-WB analysis of ROR1-EGFR association in COS-7 cotransfected with EGFR and various ROR1 deletion mutants.
(F) IP-WB analysis of the interaction between ERBB3 and p85 (PI3K), with and without siROR1 treatment, in NCI-H1975.
(G) In vitro PI3K assay with immunoprecipitated PI3K from siROR1-treated NCI-H1975 or SK-LC-5 cell lysates. Data are shown as the mean ± SD (n = 3).
(H) WB analysis of EGF-induced EGFR and ERBB3 phosphorylation in the presence or absence of siROR1 treatment in siRNA-resistant wild-type
[ROR1-mut(si#1)] or kinase-dead [ROR1-mut(si#1)] ROR1-introduced NCI-H1975 cells. See also Figure S4.
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ROR1 Sustains EGFR-Initiated Prosurvival SignalingPI3K-AKT axis (Calnan and Brunet, 2008), was also observed in
response to siROR1 treatment (Figure 4B). Interestingly, EGF
treatment induced an association of ROR1 with EGFR in NCI-
H1975 cells, as well as in COS-7 cells cotransfected with both
ROR1 and EGFR (Figures 4C and S4A, respectively). Immuno-
precipitation (IP)-western blot (WB) analysis also revealed that
ROR1 knockdown significantly reduced co-immunoprecipitation
of EGFR with ERBB3 in EGF-stimulated NCI-H1975 cells (Fig-
ure 4D). It was further shown that a cysteine-rich domain of the
extracellular domain of ROR1 is required for association with
EGFR (Figures 4E and S4B). In line with enhancement of EGF-
induced ERBB3 phosphorylation by ROR1, its knockdown led
to significantly reduced binding of the p85 subunit of PI3K to
ERBB3 (Figure 4F). In addition, an in vitro PI3K assay using
PI3K immunoprecipitated from siROR1-treated NCI-H1975 and
SK-LC-5 cell lysates showed reduced conversion of PIP3 (Fig-
ure 4G), demonstrating that ROR1 knockdown negatively affects
PI3K activity. Interestingly, both wild-type and kinase-dead
ROR1 with silent mutations at the siRNA binding site were able
to restore EGF-induced ERBB3 phosphorylation in NCI-H1975
cells, indicating that ROR1 kinase activity is not indispensable
in this regard (Figure 4H). Taken together, these findings indi-
cated that ROR1 kinase activity is not indispensable for
sustaining ROR1-EGFR interaction, EGFR-ERBB3 interaction,
and ERBB3 phosphorylation, whereas ROR1 kinase activity is
required to fully sustain downstream signaling and survival, sug-
gesting the involvement of additional downstream signaling.
Identification of c-Src as a Downstream Molecule
in ROR1-Mediated Survival Signaling
We accordingly sought an additional, underlying mechanism by
which ROR1 fully sustains survival signaling in lung adenocarci-
nomas. Contrasting changes in c-Src Y416 phosphorylation in
response to altered ROR1 expression caught our attention, since
it suggested a possible, functional relationship. We found that
introduction of constitutively active c-Src noticeably alleviated
ROR1-silencing-induced effects, including growth inhibition,
and reduced phosphorylations of PTEN and AKT, both of which
are known to be downstream of c-Src (Figure 5A; Hennessy
et al., 2005;Martin, 2001). ROR1 knockdown-induced p38 phos-
phorylation was also clearly counteracted by the introduction of
constitutively active c-Src. Of note, c-Src inactivation by either
siRNAs or a c-Src inhibitor (SKI-1) had effects very similar to
ROR1 knockdown in terms of both growth inhibition and
signaling in ROR1-positive NCI-H1975 and SK-LC-5 cells
(Figures 5B), whereas ROR1-negative NCI-H23 cells had virtually
no response to c-Src inhibition (Figure S5A). IP-WB analysis re-
vealed the interactions of exogenously introduced ROR1 with
exogenous c-Src in COS-7 cells (Figure 5C) and endogenous
c-Src in 293T cells (Figure S5B), whereas IP-WB analysis also re-
vealed the interaction between endogenous ROR1 and c-Src
proteins in NCI-H1975 cells (Figure 5D). In addition, an in vitro
pull-down assay usingGST-taggedROR1 showed an interaction
with endogenous c-Src in NCI-H1975 cell lysates (Figure S5C),
as well as with a purified c-Src protein (Figure S5D). An in vitro
ROR1 kinase assay using endogenous c-Src as a substrate in
ROR1-negative NCI-H23 and 293T cells (Figures S5E and
S5F), as well as exogenous kinase-dead c-Src the same as
that in NIH/3T3 cells (Figure 5E), revealed robust c-Src phos-phorylation. Furthermore, an association of ROR1 with the SH3
domain of c-Src was demonstrated by IP-WB analysis (Fig-
ure 5F), as well as by a GST pull-down assay (Figure S5G). In
accordance with a previous report—in which it was reported
that protein-protein interactions of c-Src are mediated by
binding of its SH3 domain with proline-rich stretches of the
binding partners (Yeatman, 2004)—the interaction between
c-Src and ROR1 required the presence of the proline-rich
domain but not kinase activity of ROR1 (Figure 5G). Whereas
PTEN has been shown to be tyrosine-phosphorylated and nega-
tively regulated by c-Src (Lu et al., 2003; Nagata et al., 2004), we
observed a decrease tyrosine phosphorylation and S380/T382/
T383 phosphorylation of PTEN in NCI-H1975 and SK-LC-5 cells
with ROR1 knockdown (Figure S5H). ROR1 knockdown-induced
growth inhibition was alleviated to a considerable extent by
silencing of PTENor p38 in NCI-H1975 cells (Figure 5H). Increase
in c-Src phosphorylation in siPTEN-treated NCI-H1975 cellsmay
reflect incomplete repression of PTEN activity, considering that
PTEN dephosphorylates c-Src (Zhang et al., 2011). Although
Wnt5a was recently suggested to mediate NF-kB signaling as
an ROR1 ligand (Fukuda et al., 2008), our preliminary data
suggest that this may not be the case in lung adenocarcinomas
(Figures S5I and S5J).
Dispensable c-Src Binding of ROR1 for ROR1-EGFR
Association and Sustainment of EGFR-ERBB3
Interaction
We next examined whether c-Src binding of ROR1 is required to
sustain ROR1-EGFR and EGFR-ERBB3 interactions. IP-WB
analysis of COS-7 cells transiently cotransfected with various
forms of ROR1 and EGFR revealed that the interaction between
ROR1 and EGFR does not require either ROR1 kinase activity or
the c-Src-interacting proline-rich domain of ROR1 (Figure 6A).
Similarly, whereas an EGF-induced interaction between EGFR
and ERBB3 was markedly enhanced by the presence of
ROR1, both kinase activity and a proline-rich domain of ROR1
were shown to be dispensable for these interactions (Figure 6B).
In addition, c-Src knockdown did not cause any appreciable
changes in the interaction between ROR1 and EGFR or between
EGFR and ERBB3 (Figure 6C). Thus, the present findings
suggest that ROR1 mediates survival signals, at least in part,
by two distinct mechanisms: ROR1 kinase-dependent c-Src-
mediated signaling and ROR1-kinase independent sustainment
of EGFR-ERBB3-PI3K signaling. In this regard, it is interesting
that rescue from siROR1-mediated effects by introduction of
exogenous wild-type ROR1 with silent mutations at the siRNA
binding site was significantly counteracted by concurrent treat-
ment with sic-Src in both NCI-H1975 and NCI-H358, whereas
such rescue was significantly counteracted by concurrent treat-
ment with siERBB3 in only NCI-H1975 but not NCI-H358 cells
(Figure 7A), suggesting possible cellular context-dependent
differences in contributions of ROR1-sustained downstream
signaling. This finding also appeared to be consistent with differ-
ential sensitivity to sic-Src and siERBB3 treatment between NCI-
H1975 and NCI-H358 cells (Figure S6A). The relative insensitivity
to siERBB3 of NCI-H358 cells with a K-ras mutation may be
consistent with a previous report of the ineffectiveness of treat-
ment with a PI3K inhibitor alone in lung adenocarcinomas occur-
ring in K-ras transgenic mice (Engelman et al., 2008). It wasCancer Cell 21, 348–361, March 20, 2012 ª2012 Elsevier Inc. 353
Figure 5. ROR1 Binds to and Phosphorylates c-Src
(A) WB (top panel) and colorimetric (bottom panel) analyses of NCI-H1975 cells introduced with siROR1 and c-Src. VC, empty vector control;WT, wild-type c-Src;
CA, constitutive active c-Src. Data are shown as the mean ± SD (n = 3). **p < 0.001 versus VC+siROR1#1, as determined by Student’s t test.
(B) Western blot (top panel) and colorimetric (bottom panel) analyses showing effects of c-Src inactivation by either siRNAs or a c-Src inhibitor (SKI-1). Data are
shown as the mean ± SD (n = 3).
(C) IP-WB analysis of the interaction between exogenous ROR1 and c-Src in COS-7.
(D) IP-WB analysis of endogenous ROR1 and c-Src using cell lysates of NCI-H1975. IgG, negative control.
(E) In vitro ROR1 kinase assay using immunoprecipitated as a substrate in kinase-dead c-Src-transfected NIH/3T3.
(F) IP-WB analysis of the ROR1-c-Src interaction using COS-7 cotransfected with myc-tagged ROR1 and various deletion mutants of c-Src.
(G) IP-WB analyses of the ROR1-c-Src interaction using mutant ROR1 constructs. WT, wild-type; KD, kinase-dead; DP, ROR1 lacking proline-rich region.
(H) WB (top panel) and colorimetric (bottom panel) analyses of NCI-H1975 cosilenced for ROR1, PTEN, and/or p38. Data are shown as themean ± SD (n = 3). See
also Figure S5.
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Figure 6. ROR1 Sustains EGFR-ERBB3 Interaction
Independent of c-Src Binding
(A) IP-WB analysis of COS-7 cells co-introduced with
EGFR and various forms of ROR1. WT, wild-type; KD,
kinase-dead; DP, ROR1 lacking proline-rich region.
(B) IP-WB analysis of COS-7 cells co-introduced with
various forms of ROR1, together with EGFR and ERBB3.
Strv, serum starved.
(C) IP-WB analysis of the interactions among ROR1,
EGFR, and ERBB3 in NCI-H1975 cells treated, with and
without sic-Src. Strv, serum starved.
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ROR1 Sustains EGFR-Initiated Prosurvival Signalingobserved that sic-Src treatment in vivo similarly inhibited both
growth and signaling in xenografts of two independent MSTO-
211H clones overexpressing ROR1, supporting the notion that
c-Src plays a crucial role as a downstream effector in this setting
(Figures 7B and S6B).
ROR1 Inhibition as a Therapeutic Option Irrespective
of EGFR Status
It is of particular interest that ROR1 knockdown inhibited the
growth of NCI-H1975 cells, because this line carries double
EGFR mutations L858R and T790M, the latter of which is a
well-recognized mutation that confers resistance to EGFR TKI
(Kobayashi et al., 2005; Pao et al., 2005). We similarly observed
growth inhibition by ROR1 knockdown in another EGFR TKI-
resistant lung adenocarcinoma cell line, NCI-H820, which carries
delE746-T751 and T790M EGFR mutations, together with MET
amplification (Figures 8A and S7A; Bean et al., 2007; Engelman
et al., 2007; Turke et al., 2010). HGF overexpression has been
postulated as an additional mechanism for resistance to EGFR
TKI by switching dependency from EGFR to MET (Yano et al.,
2008). However, treatment with siROR1 overcame HGF-medi-
ated resistance to gefitinib in the PC-9 lung adenocarcinoma
cell line with an activating EGFR mutation, which was accompa-
nied with reduction in HGF-elicited MET-transduced increase in
AKT phosphorylation, as well as decreased c-Src and increased
p38 phosphorylations (Figure 8B). It was also noted that siROR1
treatment enhanced growth inhibition in PC-9 cells when applied
along with gefitinib in the absence of HGF (Figure S7B). Whereas
gefitinib diminished ERBB3 phosphorylation to a nearly negli-
gible level in the NCI-H358 lung adenocarcinoma cell line, which
is known to be relatively sensitive to gefitinib despite wild-typeCancer Cell 21, 3EGFR status (Engelman et al., 2005), concurrent
siROR1 treatment with gefitinib further en-
hanced inhibition of cell growth in association
with a clear reduction in remaining AKT phos-
phorylation (Figure 8C). Together, these findings
suggest that ROR1 inhibition may be a thera-
peutic option for ROR1-positive lung adenocar-
cinomas irrespective of their EGFR status.
DISCUSSION
Accumulated evidence indicates that NKX2-1, a
lineage-specific transcription factor with essen-
tial roles in peripheral lung development (Maeda
et al., 2007), is expressed in a major fraction oflung adenocarcinomas (Yatabe et al., 2002). Although previous
studies, including ours, demonstrated the requirement of sus-
tained NKX2-1 expression for lung adenocarcinoma survival
(Kendall et al., 2007; Kwei et al., 2008; Tanaka et al., 2007;
Weir et al., 2007), the mechanism by which NKX2-1 mediates,
survival signals remains elusive. The present study clearly
showed that ROR1 is a direct transcriptional target of NKX2-1
and is crucially involved in sustainment of a favorable balance
between prosurvival PI3K-AKT signaling and the pro-apoptotic
p38 pathway (Figures 8D), collapse of which elicits ‘‘oncogenic
shock’’ (Sharma et al., 2006). Our previous studies revealed
a significant association of NKX2-1 expression with EGFRmuta-
tions in lung adenocarcinomas (Takeuchi et al., 2006; Yatabe
et al., 2005), suggesting their potential functional linkage. In
this regard, the present findings suggest that NKX2-1 and
EGFR may be functionally interrelated with each other through
NKX2-1-mediated ROR1 induction in lung adenocarcinoma
cells, which conceivably contributes to the development of
lung adenocarcinomas with characteristic features. In addition,
when considering the significant, yet incomplete, rescue from
siNKX2-1-induced growth inhibition by ROR1 overexpression,
an additional downstream target(s) may be involved in NKX2-
1-mediated survival signaling.
The present results also demonstrate that ROR1 employs
distinct kinase-dependent and -independent mechanisms to
sustain a favorable balance between PI3K-AKT-mediated pro-
survival signaling and the pro-apoptotic p38pathway (Figure 8D).
EGFR exists in a conformation that is unable to interact with
ERBB3 and requires a ligand-engagement-elicited conforma-
tional change of the extracellular domain for dimerization-
competence acquisition (Linggi and Carpenter, 2006). We found48–361, March 20, 2012 ª2012 Elsevier Inc. 355
Figure 7. ROR1 Sustains Downstream Signaling via c-Src and ERBB3 in a Cellular Context-Dependent Manner
(A) Colorimetric assay (bottom panel) and WB analysis (top panel) of NCI-H1975 and NCI-H358 cells introduced with RNAi-resistant wild-type ROR1
[ROR1-mut(si#1)] and treated with siROR1, along with either sic-Src or siERBB3. Data are shown as the mean ± SD (n = 3). **p < 0.001 versus siROR1#1+ROR1-
WTmut(si#1), as determined by Student’s t test.
(B) In vivo tumor growth assay (bottom panel) andWB analysis (top panel) of xenografts of MSTO-211H, stably expressing exogenous ROR1, which were treated
in vivo with sic-Src or siERBB3. Data are shown as the mean ± SD (n = 6). **p < 0.001 versus siControl +ROR1, as determined by Student’s t test. See also
Figure S6.
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Figure 8. ROR1 Repression Inhibits Lung Adenocarcinomas, Irrespective of the EGFR Status
(A) WB analysis of cleaved caspase-3 (top panel) and a colorimetric assay (bottom panel) of NCI-H1975 and NCI-H820 knocked down for ROR1. Data are shown
as the mean ± SD (n = 3).
(B) WB analysis of downstream molecules and a colorimetric assay of gefitinib and/or HGF treatment of siROR1-teated PC-9 cells. Data are shown as the
mean ± SD (n = 3).
(C) Effects of siROR1 treatment in the relatively gefitinib-sensitive lung adenocarcinoma cell line NCI-H358. Data are shown as the mean ± SD (n = 3).
(D) Proposed model of how ROR1 plays a key role in sustaining a favorable balance between prosurvival and pro-apoptotic signaling. Two distinct mechanisms
appear to coexist in sustaining prosurvival signaling: (1) ROR1 kinase-dependent c-Src activation and (2) kinase-independent sustainment of EGFR-ERBB3
association and consequential ERBB3 phosphorylation. See also Figure S7.
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Cancer Cell
ROR1 Sustains EGFR-Initiated Prosurvival Signalingthat ROR1 plays a role independent of its kinase activity in sus-
tainment of EGF-induced signaling of the EGFR-ERBB3-PI3K
axis, which is well known to play a crucial role in lung adenocar-
cinomas. Interestingly, we also observed that EGF treatment
elicited robust phosphorylations of both EGFR at Y1068 and
ERK, even in cells knocked down for ROR1. These findings indi-
cate that ROR1 interaction with EGFR is selectively required for
sustainment of signaling along the EGFR-ERBB3-PI3K axis
through EGFR-ERBB3 heterodimerization and resultant ERBB3
phosphorylation but not for signaling toward the ERK pathway
through autophosphorylation and homodimerization of EGFR.
It is anticipated that future studies detailing the high-resolution
structures of these receptors would provide insight into how
ROR1 participates in this process with such specificity.
We previously showed that ROR1 physically interacts with and
phosphorylates c-Src, which is a critical component of multiple
signaling pathways important for cancer development (Yeatman,
2004). In addition, we noted that PTEN negative regulation of
PI3K-AKT signaling appears to be, at least in part, under the
influence of ROR1 expression, a finding consistent with previous
reports on PTEN as a c-Src substrate (Lu et al., 2003; Nagata
et al., 2004). It is also interesting to note that c-Src-mediated
tyrosine phosphorylation has been proposed to trigger T308
and S473 phosphorylations by PDK1 and mTORC2, respec-
tively, leading to AKT activation (Bellacosa et al., 1998; Chen
et al., 2001; Jiang and Qiu, 2003) and lending support for the
notion that ROR1-mediated c-Src activation may be also
involved in this prerequisite process for robust AKT activation
in lung adenocarcinoma cells. Thus, ROR1 appears to play
a role independent of kinase activity in sustainment of EGF-
induced signaling through the EGFR-ERBB3-PI3K axis, which
is further upheld by ROR1 downstream through its kinase-
dependent c-Src activation. It is also possible that there may
be additional substrates of ROR1, as is generally the case in
receptor tyrosine kinase signaling.
Taken together, the present findings identify ROR1 as an
‘‘Achilles’ heel’’ in lung adenocarcinomas. Mechanisms, such
as secondary EGFRmutation, MET amplification, and HGF over-
expression, may arise in lung adenocarcinomas in patients
undergoing EGFR-TKI treatment, leading to resistance to treat-
ment by the tumors. The existence of such diverse mechanisms
make it difficult to predict which should be targeted to prevent
expansion of resistant clones (Bean et al., 2007; Engelman
et al., 2007; Turke et al., 2010; Yano et al., 2008). From a clinical
point of view, it is of particular interest that ROR1 inhibition
appears to be effective for treatment of gefitinib-resistant lung
adenocarcinomas with various resistance mechanisms. To
date, very little is known about the functions of ROR1 and its
role in human cancers, in accordance with its name, that is, tyro-
sine kinase-like orphan receptor 1 (Forrester, 2002; Green et al.,
2008; Minami et al., 2010). Interestingly, upregulation of ROR1
was recently reported in chronic lymphocytic leukemia (Baskar
et al., 2008; Daneshmanesh et al., 2008; Fukuda et al., 2008).
In addition, it is notable that NKX2-1 is expressed in small
cell lung cancers at a high frequency (Kitamura et al., 2009).
Future development of therapeutic means including ROR1-
specific antibodies and small molecules that inhibit both or
either of the two distinct prosurvival signal-sustaining functions
is greatly anticipated for attempts to reduce the intolerable358 Cancer Cell 21, 348–361, March 20, 2012 ª2012 Elsevier Inc.death toll from currently ‘‘hard-to-cure’’ lung adenocarcinomas,
as well as possibly other ROR1-positive cancers.
EXPERIMENTAL PROCEDURES
Cell Lines and Tissues
NCI-H1975, NCI-H820, NCI-H441, NCI-H358, NCI-H23, and PC-9 cells were
purchased from the American Type Culture Collection. The derivations and
culture conditions of other human cancer cell lines, as well as the immortalized
human lung epithelial cell line HPL1D, have been reported (Tanaka et al., 2007).
Their characteristics are summarized in Table S1. Human cancer and normal
tissues as well as primary normal lung epithelial cells were obtained under
approval from the institutional review board of Nagoya University with written
informed consent from each patient.
Constructs
The methods used for the construction of the expression constructs of
full-length human NKX2-1 cDNA in pCMV-puro (pCMVpuro-NKX2-1), as
well as of short hairpin RNA (shRNA) against NKX2-1 in pH1RNAneo
(pH1RNAneo-shNKX2-1), have been described (Tanaka et al., 2007). Full-
length human ROR1 cDNA (OriGene Technologies, Rockville, MDs) was
inserted into a pCMV-puro vector, and the entire open reading frame of the
resulting construct (pCMVpuro-ROR1) was thoroughly sequenced.
pCMVpuro-ROR1-KD (an inactivating K506A mutation at the ATP binding
site), pCMVpuro-ROR1-DP, and pCMVpuro-ROR1-DCRD were constructed
by in vitro mutagenesis using KOD-plus-DNA polymerase (Toyobo, Osaka,
Japan). In addition, a myc-tagged derivative of pIRESpuro2-ROR1
(pIRESpuro2-ROR1-myc) and its derivatives (pIRESpuro2-ROR1-DN-myc
and pIRESpuro2-ROR1-DC-myc) were constructed. pIRESpuro2-ROR1-DIg-
myc, pIRESpuro2-ROR1-DCRD-myc, pIRESpuro2-ROR1-DKringle-myc, pIR-
ESpuro2-ROR1-DIg+CRD-myc, pIRESpuro2-ROR1-DCRD+Kringle-myc, and
pIRESpuro2-ROR1-DIg+CRD+Kringle-myc were also constructed by in vitro
mutagenesis using a KOD-plus-DNA polymerase.
Full-length human EGFR cDNA was purchased from Riken and inserted into
a pCMV-puro vector (pCMVpuro-EGFR). Full-length human ERBB3 cDNA
(pcDNA5/FRT-ERBB3) was kindly provided by N. Taniguchi (Osaka University,
Osaka, Japan). pNeo-MSV-c-Src wild-type (WT), constitutive active (CA), and
kinase dead (KD) were kindly provided by T. Hunter (Salk Institute, La Jolla, CA;
Broome and Hunter, 1996), and the inserts were transferred into pCMVpuro,
resulting in the following: pCMVpuro-WT-c-Src, pCMVpuro-CA-c-Src, and
pCMVpuro-KD-c-Src. pRC-CMV-c-Src wild-type (WT), D15-84 (D15),
D90-144 (D90), and D150-246 (D150) were kindly provided by S.J. Shattil
(University of California San Diego, San Diego, CA, USA; Arias-Salgado
et al., 2003).
Microarray Analysis
HPL1D cells stably expressing NKX2-1 (HPL1D-NKX2-1) were generated by
transfecting pCMVpuro-NKX2-1 using FuGENE6, followed by puromycin
selection. RNA was extracted from HPL1D-NKX2-1 and its empty control
vector HPL1D-VC and then analyzed in dye-swapped duplicate using a low
RNA fluorescent linear amplification kit and 44K whole human genome micro-
arrays (Agilent Technologies, Santa Clara, CA), in accordance with the manu-
facturer’s instructions. HPL1D cells were also transiently transfected with
NKX2-1, selected with puromycin for three days, and harvested for validation
of ROR1 induction by western blot analysis.
Western Blot and Immunoprecipitation-Western Blot Analyses
Western blot and immunoprecipitation-western blot analyses were performed
using standard procedures with Immobilon-P filters (Millipore, Billerica, MA)
and an enhanced chemiluminescence system (GE Healthcare, Buckingham-
shire, UK). For analysis of physical interactions between ROR1 and c-Src,
pIRESpuro2-ROR1-myc was transfected with various c-Src expression
constructs, including wild-type (WT), D15-84 c-Src (D15), D90-144 c-Src
(D90), or D150-246 c-Src (D150). Similarly, wild-type c-Src was transfected
with pCMVpuro-ROR1 (ROR1), pCMVpuro-ROR1-K506A (ROR1-KD), or
pCMVpuro-ROR1–DP (ROR1-DP). Cells were harvested 24 hr after transfec-
tion with the lysis buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl,
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1 mM b-glycerophosphate, 1 mM Na3VO4, 1 mg/ml leupeptin, 1 mM PMSF,
and Complete (EDTA-free protease inhibitor mixture; Roche, Mannheim, Ger-
many). For analysis of physical interactions among ROR1, EGFR, and ERBB3,
pCMVpuro-EGFR and/or pcDNA5/FRT-ERBB3 were transfected with various
ROR1 expression constructs, including wild-type (WT), DN, DC, DIg, DCRD,
DKringle, DIg+CRD, DCRD+Kringle, and DIg+CRD+Kringle. Cells were
serum-starved for 24 hr, treated with 20 ng/ml of EGF 48 hr after transfection
for up to 30 min, and then harvested to analyze their interactions through
immunoprecipitation-western blot analysis. A NP-40 lysis buffer containing
20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 2 mM EDTA, 1% NP-40, 10% Glyc-
erol, and 1 mM Na3VO4 was used to investigate the physical interactions
among ROR1, EGFR, and ERBB3.
Clarification of ROR1-RNAi Effects
pCMVpuro-ROR1-WT-mut(si#1) and pCMVpuro-ROR1-KD-mut(si#1), which
carry multiple silent mutations at the binding site of siROR1#1, were con-
structed by in vitro mutagenesis using KOD-plus-DNA Polymerase (Toyobo)
and the oligonucleotide primer 50-CAACAGTGGACAGAGTTCCAG-30
(mutated residues are underlined). NCI-H1975 and NCI-H358 at 2.0 3 106
were transfected with an empty pCMVpuro vector (VC), pCMVpuro-
ROR1 (ROR1), pCMVpuro-ROR1-WT-mut(si#1) [ROR1-WT-mut(si#1)], or
pCMVpuro-ROR1-KD-mut(si#1) [ROR1-KD-mut(si#1)], followed by puromycin
selection (1.5 mg/ml) for three days. The resulting bulk transfectants were then
re-seeded into 6-well plates and further introducedwith siROR1 alone or along
with either sic-Src or siERBB3 on the next day. Cells were harvested for
western blot analysis at three days or a colorimetric assay at five days after
siRNA transfection. For rescue experiments of ERBB3 phosphorylation, NCI-
H1975 cells expressing ROR1-WT-mut(si#1) or ROR1-KD-mut(si#1) were
transfected with siROR1 or siControl and then serum-starved for 24 hr. After
treatment with 20 ng/ml of EGF for various time periods, western blot analyses
were performed.
Analyses of Functional Relationships of ROR1 with NKX2-1
and c-Src
In order to analyze the effects of exogenous ROR1 expression in shNKX2-1-
treated lung adenocarcinoma cells, pH1RNAneo-shNKX2-1 and pCMVpuro-
ROR1 were cotransfected into NCI-H358 at a ratio of 1:4, followed by
neomycin selection for two weeks before counting the number of colonies.
The functional relationship between ROR1 and c-Src was analyzed in NCI-
H1975 cells by transfection of pCMVpuro-WT-c-Src or pCMVpuro-CA-c-
Src; then, transfected cells were selected with puromycin for three days.
The resulting bulk transfectants were then re-seed into 6-well plates and
further introduced with siROR1 or siControl. Cells were harvested for western
blot analysis at 72 hr after siRNA transfection. A colorimetric assay was per-
formed five days after siRNA transfection. NCI-H1975, SK-LC-5, and NCI-
H23 cells were also treated with the Src kinase inhibitor SKI-1 at 5 mM for
6 hr and harvested for western blot analysis. For a colorimetric assay, cells
were treated with 5 mM SKI-1 for five days.
In Vivo Tumorigenicity Assays
NCI-H1975 cells at 1.0 3 107 were subcutaneously inoculated into the
lower flanks of 8-week-old athymic nude mice (Japan SLC, Shizuoka,
Japan). One week after inoculation, a mixture of 1 nmol of siRNAs (siROR1
#1, #2, and #3) and 200 ml of atelocollagen (Koken, Tokyo, Japan) was
injected into the tumors, which had an average volume of 50 mm3. Tumor
weights were measured two weeks after siRNA injection. In vivo tumorige-
nicity assays were also performed by subcutaneous inoculation of
1.0 3 107 MSTO-211H cells stably expressing wild-type ROR1 (ROR1#1
and #2), kinase-dead ROR1 (ROR1-KD#1 and #2), or those introduced
with an empty vector (VC#1 and #2) into the lower flanks of 8-week-old
athymic nude mice (Japan SLC). In this experiment, tumor weights
were determined three weeks after inoculation. In addition, tumors
were analyzed by western blot analysis for detection of various protein
expressions. For analysis of the effects of c-Src or ERBB3 knockdown in
the ROR1 transfectants, a mixture of 1 nmol siRNAs (siControl, sic-Src
#1, sic-Src #2, siERBB3 #1, or siERBB3 #2) and 200 ml atelocollagen was
injected into the tumors at one week after inoculation. Tumor weightswere measured two weeks after siRNA injection and various protein
expressions were analyzed by western blot analysis. All animal experiments
were performed in compliance with the regulations for animal experiments
of Nagoya University.
EGF, HGF, and/or Gefitinib Treatment in Cells Knocked Down
for ROR1
NCI-H1975 and SK-LC-5 cells (1.0 3 105) were transfected with 20 nM
siROR1 or siControl and then serum-starved for 24 hr. After treatment with
20 ng/ml of EGF for various time periods, western blot and immunofluores-
cent staining analyses were performed. NCI-H1975, NCI-H820, and NCI-
H358 cells (1.0 3 105) were transfected with 20 nM siROR1 or siControl,
then cultured for three days before treatment with 1 mM gefitinib for 6 hr,
and harvested for western blot analysis. For a colorimetric assay, cells
(5.0 3 104) were transfected with the siRNAs and then continuously exposed
to 1 mM gefitinib for four days. Similarly, three days after siRNA transfection,
PC-9 cells were treated with 1 mM gefitinib and/or 50 ng/ml of HGF for 6 hr
and then harvested for western blot analysis. Effects on cell proliferation
were also examined by a colorimetric assay after a four-day exposure to
1 mM gefitinib and/or 50 ng/ml of HGF, which was initiated the day after
siRNA transfection.
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